Afshar Oromieh, AliAliAfshar OromiehDebus, NilsNilsDebusUhrig, MonikaMonikaUhrigHope, Thomas A.Thomas A.HopeEvans, Michael J.Michael J.EvansHolland-Letz, TimTimHolland-LetzGiesel, Frederik L.Frederik L.GieselKopka, KlausKlausKopkaHadaschik, BorisBorisHadaschikKratochwil, ClemensClemensKratochwilHaberkorn, UweUweHaberkorn2024-10-082024-10-082018-07-07https://boris-portal.unibe.ch/handle/20.500.12422/63599PURPOSE: Since the introduction of PSMA PET/CT with 68Ga-PSMA-11, this modality for imaging prostate cancer (PC) has spread worldwide. Preclinical studies have demonstrated that short-term androgen deprivation therapy (ADT) can significantly increase PSMA expression on PC cells. Additionally, retrospective clinical data in large patient cohorts suggest a positive association between ongoing ADT and a pathological PSMA PET/CT scan. The present evaluation was conducted to further analyse the influence of long-term ADT on PSMA PET/CT findings. METHODS: A retrospective analysis was performed of all 1,704 patients who underwent a 68Ga-PSMA-11 PET/CT scan at our institution from 2011 to 2017 to detect PC. Of 306 patients scanned at least twice, 10 had started and continued ADT with a continuous clinical response between the two PSMA PET/CT scans. These ten patients were included in the current analysis which compared the tracer uptake intensity and volume of PC lesions on PSMA PET/CT before and during ongoing ADT. RESULTS: Overall, 31 PC lesions were visible in all ten patients before initiation of ADT. However, during ongoing ADT (duration 42-369 days, median 230 days), only 14 lesions were visible in eight of the ten patients. The average tracer uptake values decreased in 71% and increased in 12.9% of the PC lesions. Of all lesions, 33.3% were still visible in six patients with a complete PSA response (≤0.1 ng/ml). CONCLUSION: Continuous long-term ADT significantly reduces the visibility of castration-sensitive PC on PSMA PET/CT. If the objective is visualization of the maximum possible extent of disease, we recommend referring patients for PSMA PET/CT before starting ADT. KEYWORDS: 68Ga-PSMA-11; Androgen deprivation therapy; PET/CT; PSMA; Prostate cancer; Prostate-specific membrane antigenen600 - Technology::610 - Medicine & healtharticle10.7892/boris.1256142998083210.1007/s00259-018-4079-z